ATE461197T1 - 1,8-naphthyridine als crf antagonisten - Google Patents

1,8-naphthyridine als crf antagonisten

Info

Publication number: ATE461197T1
Authority: AT; Austria
Prior art keywords: alkyl; halo; alkoxy; halogen; hydrogen
Prior art date: 2001-07-17

Application number

AT06076176T

Other languages

English (en)

Inventor

Fabio Romano Di

Fabrizio Micheli

Yves St-Denis

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-17

Filing date

2002-07-15

Publication date

2010-04-15

2002-07-15 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE461197T1 publication Critical patent/ATE461197T1/de

Links

239000005557 antagonist Substances 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
229910052736 halogen Inorganic materials 0.000 abstract 4
150000002367 halogens Chemical class 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
-1 -NR 6 R 7 Chemical group 0.000 abstract 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
125000004093 cyano group Chemical group *C#N 0.000 abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT06076176T 2001-07-17 2002-07-15 1,8-naphthyridine als crf antagonisten ATE461197T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0117396.2A GB0117396D0 (en)	2001-07-17	2001-07-17	Chemical compounds

Publications (1)

Publication Number	Publication Date
ATE461197T1 true ATE461197T1 (de)	2010-04-15

Family

ID=9918655

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06076176T ATE461197T1 (de)	2001-07-17	2002-07-15	1,8-naphthyridine als crf antagonisten
AT02764696T ATE338042T1 (de)	2001-07-17	2002-07-15	Hetero-bicyclische crf antagonisten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02764696T ATE338042T1 (de)	2001-07-17	2002-07-15	Hetero-bicyclische crf antagonisten

Country Status (26)

Country	Link
US (2)	US7253284B2 (de)
EP (2)	EP1695974B1 (de)
JP (1)	JP4459616B2 (de)
KR (2)	KR100961287B1 (de)
CN (1)	CN100447141C (de)
AT (2)	ATE461197T1 (de)
AU (1)	AU2002328899B2 (de)
BR (1)	BR0211171A (de)
CA (1)	CA2451530A1 (de)
CO (1)	CO5550437A2 (de)
CY (1)	CY1105780T1 (de)
DE (2)	DE60235729D1 (de)
DK (1)	DK1425280T3 (de)
ES (2)	ES2271327T3 (de)
GB (2)	GB0117396D0 (de)
HU (1)	HUP0400465A2 (de)
IL (1)	IL159254A0 (de)
MX (1)	MXPA04000494A (de)
NO (1)	NO20040206L (de)
NZ (1)	NZ530043A (de)
PL (1)	PL368053A1 (de)
PT (1)	PT1425280E (de)
RU (1)	RU2310655C2 (de)
SI (1)	SI1425280T1 (de)
WO (1)	WO2003008412A2 (de)
ZA (1)	ZA200309708B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE397609T1 (de) *	2001-06-12	2008-06-15	Glaxo Group Ltd	Corticotropinfreisetzungsfaktor antagonisten
EP1583531B1 (de) *	2003-01-16	2007-04-18	SB Pharmco Puerto Rico Inc	Heteroaryl-substituierte pyrrol[2, 3- b]pyridin-derivate als crf-rezeptor-antagonisten
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
JP4926720B2 (ja)	2003-12-22	2012-05-09	スミスクラインビーチャム（コーク）リミテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7652035B2 (en) *	2004-10-19	2010-01-26	Neurocrine Bioscience, Inc.	CRF receptor antagonists and methods relating thereto
US8088779B2 (en)	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8513420B2 (en)	2007-03-19	2013-08-20	Monika Mazik	Amino-naphthyridine derivatives
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009008552A1 (en) *	2007-07-11	2009-01-15	Taisho Pharmaceutical Co., Ltd.	8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2015009270A (es)	2013-01-18	2015-10-30	Hoffmann La Roche	Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP2968439A2 (de)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Zusammensetzungen zur behandlung von magen-darm-störungen

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK160306C (da) *	1978-08-31	1991-07-29	Otsuka Pharma Co Ltd	Analogifremgangsmaade til fremstilling af piperazinylbenzoheterocycliske forbindelser eller farmaceutisk acceptable salte deraf
US5169857A (en) *	1988-01-20	1992-12-08	Bayer Aktiengesellschaft	7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
GB2248618B (en)	1988-06-17	1993-01-06	Wyeth John & Brother Ltd	Process for preparing pyridine derivatives
CA2022408A1 (en)	1989-08-31	1991-03-01	Michael P. Bodman	Process for preparing pyridine carboxylic acid derivatives
KR0155955B1 (ko) *	1989-10-11	1998-11-16	이따가끼 히로시	2 환성 피리미딘 유도체, 그의 제조방법 및 그를 유효성분으로 하는 의약제제
DE4022414A1 (de) *	1990-07-13	1992-01-16	Bayer Ag	Substituierte pyrrolo-pyridine
WO1992012718A1 (en)	1991-01-23	1992-08-06	Gensia, Inc.	Adenosine kinase inhibitors
US5246944A (en) *	1991-08-13	1993-09-21	Merck & Co., Inc.	Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
GB9125842D0 (en)	1991-12-04	1992-02-05	Ici Plc	Heterocyclic derivatives
PT633886E (pt)	1992-04-03	2001-03-30	Upjohn Co	Aminas biciclicas-heterociclicas farmaceuticamente activas
US5502187A (en) *	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
JPH0710876A (ja)	1993-06-24	1995-01-13	Teijin Ltd	４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
JP3398152B2 (ja)	1993-10-12	2003-04-21	ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー	１ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
NZ274978A (en) *	1993-10-12	1998-04-27	Du Pont Merck Pharma	1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
ES2135062T3 (es)	1994-06-16	1999-10-16	Pfizer	Pirazolo y pirrolopiridinas.
EP0729758A3 (de)	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidine und Pyrrolopyrimidine zur Behandlung von neuronalen und anderen Krankheiten
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
AU738304B2 (en) *	1995-10-13	2001-09-13	Neurogen Corporation	Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en)	1995-10-13	1999-09-21	Neurogen Corporation	Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
DK0920429T3 (da)	1996-08-06	2003-05-12	Pfizer	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
TW477787B (en) *	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
PL332040A1 (en) *	1996-08-28	1999-08-16	Pfizer	Substitution 6,5-heterobicyclic derivatives
JP2001511813A (ja)	1997-02-18	2001-08-14	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
WO1999007703A1 (en)	1997-08-05	1999-02-18	Pfizer Products Inc.	4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
US6310063B1 (en)	1998-04-02	2001-10-30	Neurogen Corporation	Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
JPH11335376A (ja)	1998-05-25	1999-12-07	Taisho Pharmaceut Co Ltd	アリールテトラヒドロピリジン誘導体
JP2000086663A (ja)	1998-09-09	2000-03-28	Taisho Pharmaceut Co Ltd	アリールテトラヒドロピリジン誘導体
DE60003899T2 (de)	1999-03-11	2004-05-27	Neurogen Corp., Branford	Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
ATE247652T1 (de)	1999-03-29	2003-09-15	Neurogen Corp	4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
FR2791675B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
EP1040831A3 (de)	1999-04-02	2003-05-02	Pfizer Products Inc.	Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes
JP2002543200A (ja)	1999-04-30	2002-12-17	ニューロゲンコーポレイション	９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
AU7738000A (en)	1999-09-30	2001-04-30	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
US6525067B1 (en)	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
CA2397633A1 (en)	2000-01-18	2001-07-26	Pfizer Products Inc.	Corticotropin releasing factor antagonists
AR028782A1 (es)	2000-07-05	2003-05-21	Taisho Pharmaceutical Co Ltd	Derivados heterociclicos tetrahidropiridino o piperidino
AU2001284417A1 (en)	2000-09-05	2002-03-22	Taisho Pharmaceutical Co. Ltd.	Hair growth stimulants
GB0100622D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds V111
US20040110785A1 (en)	2001-02-02	2004-06-10	Tao Wang	Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CA2446514A1 (en) *	2001-04-30	2002-11-07	Glaxo Group Limited	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) *	2001-06-12	2008-06-15	Glaxo Group Ltd	Corticotropinfreisetzungsfaktor antagonisten
WO2003022214A2 (en)	2001-09-06	2003-03-20	Millennium Pharmaceuticals, Inc.	Piperazine and homopiperazine compounds
SE0201980D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
EP1583531B1 (de)	2003-01-16	2007-04-18	SB Pharmco Puerto Rico Inc	Heteroaryl-substituierte pyrrol[2, 3- b]pyridin-derivate als crf-rezeptor-antagonisten
WO2004074286A1 (en) *	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds

2001
- 2001-07-17 GB GBGB0117396.2A patent/GB0117396D0/en not_active Ceased
2002
- 2002-07-11 GB GB0216041A patent/GB2378702A/en not_active Withdrawn
- 2002-07-15 NZ NZ530043A patent/NZ530043A/xx unknown
- 2002-07-15 SI SI200230419T patent/SI1425280T1/sl unknown
- 2002-07-15 US US10/483,792 patent/US7253284B2/en not_active Expired - Fee Related
- 2002-07-15 CA CA002451530A patent/CA2451530A1/en not_active Abandoned
- 2002-07-15 ES ES02764696T patent/ES2271327T3/es not_active Expired - Lifetime
- 2002-07-15 DE DE60235729T patent/DE60235729D1/de not_active Expired - Lifetime
- 2002-07-15 HU HU0400465A patent/HUP0400465A2/hu unknown
- 2002-07-15 WO PCT/EP2002/007865 patent/WO2003008412A2/en not_active Ceased
- 2002-07-15 PT PT02764696T patent/PT1425280E/pt unknown
- 2002-07-15 MX MXPA04000494A patent/MXPA04000494A/es active IP Right Grant
- 2002-07-15 PL PL02368053A patent/PL368053A1/xx unknown
- 2002-07-15 EP EP06076176A patent/EP1695974B1/de not_active Expired - Lifetime
- 2002-07-15 CN CNB02813866XA patent/CN100447141C/zh not_active Expired - Fee Related
- 2002-07-15 DE DE60214401T patent/DE60214401T2/de not_active Expired - Lifetime
- 2002-07-15 ES ES06076176T patent/ES2342417T3/es not_active Expired - Lifetime
- 2002-07-15 DK DK02764696T patent/DK1425280T3/da active
- 2002-07-15 AT AT06076176T patent/ATE461197T1/de not_active IP Right Cessation
- 2002-07-15 KR KR1020047000696A patent/KR100961287B1/ko not_active Expired - Fee Related
- 2002-07-15 KR KR1020097020632A patent/KR20090110386A/ko not_active Ceased
- 2002-07-15 EP EP02764696A patent/EP1425280B1/de not_active Expired - Lifetime
- 2002-07-15 AU AU2002328899A patent/AU2002328899B2/en not_active Ceased
- 2002-07-15 BR BR0211171-3A patent/BR0211171A/pt not_active IP Right Cessation
- 2002-07-15 RU RU2004104349/04A patent/RU2310655C2/ru not_active IP Right Cessation
- 2002-07-15 JP JP2003513971A patent/JP4459616B2/ja not_active Expired - Fee Related
- 2002-07-15 AT AT02764696T patent/ATE338042T1/de not_active IP Right Cessation
- 2002-07-15 IL IL15925402A patent/IL159254A0/xx unknown
2003
- 2003-12-15 ZA ZA200309708A patent/ZA200309708B/xx unknown
2004
- 2004-01-16 CO CO04002410A patent/CO5550437A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040206A patent/NO20040206L/no not_active Application Discontinuation
2006
- 2006-11-14 CY CY20061101650T patent/CY1105780T1/el unknown
2007
- 2007-05-16 US US11/749,433 patent/US20070219232A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2310655C2 (ru)	2007-11-20
KR20040023651A (ko)	2004-03-18
ZA200309708B (en)	2005-01-21
HUP0400465A2 (hu)	2005-01-28
KR20090110386A (ko)	2009-10-21
GB0216041D0 (en)	2002-08-21
CA2451530A1 (en)	2003-01-30
DE60235729D1 (de)	2010-04-29
ES2271327T3 (es)	2007-04-16
CN100447141C (zh)	2008-12-31
JP4459616B2 (ja)	2010-04-28
NZ530043A (en)	2006-03-31
PT1425280E (pt)	2006-12-29
JP2005514328A (ja)	2005-05-19
US20040171607A1 (en)	2004-09-02
CY1105780T1 (el)	2011-02-02
ATE338042T1 (de)	2006-09-15
MXPA04000494A (es)	2004-05-04
SI1425280T1 (sl)	2006-12-31
DK1425280T3 (da)	2007-01-02
BR0211171A (pt)	2004-08-10
US20070219232A1 (en)	2007-09-20
US7253284B2 (en)	2007-08-07
RU2004104349A (ru)	2005-03-27
DE60214401T2 (de)	2007-02-22
NO20040206L (no)	2004-03-16
CN1525972A (zh)	2004-09-01
WO2003008412A2 (en)	2003-01-30
IL159254A0 (en)	2004-06-01
HK1066535A1 (en)	2005-03-24
EP1695974B1 (de)	2010-03-17
AU2002328899B2 (en)	2006-12-21
WO2003008412A3 (en)	2003-05-01
GB2378702A (en)	2003-02-19
DE60214401D1 (de)	2006-10-12
ES2342417T3 (es)	2010-07-06
PL368053A1 (en)	2005-03-21
CO5550437A2 (es)	2005-08-31
GB0117396D0 (en)	2001-09-05
EP1425280A2 (de)	2004-06-09
KR100961287B1 (ko)	2010-06-04
EP1425280B1 (de)	2006-08-30
EP1695974A1 (de)	2006-08-30

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60235729D1 (de)	2010-04-29	1,8-Naphthyridine als CRF Antagonisten
TW200508232A (en)	2005-03-01	Bicyclic derivatives, their preparation, pharmaceutical compositions containing them and their use in therapy
YU31303A (sh)	2006-05-25	Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi
NO20055421L (no)	2005-12-20	Kinolinderivater som fosfodiestrase-inhibitorer
EA200700099A1 (ru)	2007-08-31	Производные пиридина
ATE301653T1 (de)	2005-08-15	Pyrazolopyridine
MXPA05012247A (es)	2006-02-10	Derivados de bencimidazol nuevos.
DE602004005960D1 (de)	2007-05-31	Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
DE60221425D1 (de)	2007-09-06	Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
ATE337318T1 (de)	2006-09-15	Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
ATE397609T1 (de)	2008-06-15	Corticotropinfreisetzungsfaktor antagonisten
ATE316972T1 (de)	2006-02-15	Trizyklische crf rezeptor antagonisten
ATE452636T1 (de)	2010-01-15	3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen
ES2182755T3 (es)	2003-03-16	Compuestos de tetrazolilalquilindol como agentes antiinflamtorios y analgesicos.
TH101406B (th)	2010-05-26	สารประกอบตัวใหม่